Sanitam Partners LLC - 08 Apr 2025 Form 4/A - Amendment Insider Report for Matinas BioPharma Holdings, Inc. (MTNB)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MTNB	Series C Convertible Preferred Stock	Purchase	$703,000	+703	+100%	$1000.00^*	1,406	08 Apr 2025	Common Stock	1,199,659	$0.5860	Direct	F1, F2, F3
transaction	MTNB	Warrants	Purchase		+2,399,318	+100%		4,798,636	08 Apr 2025	Common Stock	2,399,318	$0.6446	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	Pursuant to the Securities Purchase Agreement, dated February 13, 2025, Sanitam purchased an aggregate of 1,406 shares of the Issuer's Series C Convertible Preferred Stock, par value $0.0001 per share (the "Preferred Stock") with a stated value of $1,000 per share of Preferred Stock, and 4,798,636 Warrants for gross proceeds of $1,406,000.00. The Preferred Stock and Warrants were sold in two tranches with each tranche consisting of 703 shares of Preferred Stock and 2,399,318 Warrants.
F2	Each holder of Preferred Stock is entitled to vote on an as-converted to Common Stock basis with a per share voting price of $0.6393, granting Sanitam voting power from the Preferred Strock of up to 30.2% of the outstanding Common Stock. Sanitam's beneficial ownership is subject to a 9.99% limit on the shares of Common Stock issuable upon conversion of the Preferred Stock and a 4.99% limit on the shares of Common Stock issuable upon exercise of the Warrants.
F3	N/A